triamcinolone acetonide and almagate
triamcinolone acetonide has been researched along with almagate in 18 studies
Research
Studies (18)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (55.56) | 29.6817 |
2010's | 8 (44.44) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Menéndez de Lucas, JA; Morcillo Laiz, R | 1 |
Bandello, F; Chakravarthy, U; Chong, V; Creuzot-Garcher, C; Dimitrakos, SA; Korobelnik, JF; Larsen, M; Monés, J; Pauleikhoff, D; Pournaras, CJ; Soubrane, G; Staurenghi, G; Virgili, G; Wolf, S | 1 |
Chaudhry, NA; Colina, J; Haffner, G; Liggett, PE; Tom, D | 1 |
Bienias, W; Nowak, JZ | 1 |
Criswell, MH; Hu, WZ; Li, R; Margaron, P; Steffens, TJ | 1 |
Covert, DJ; Hur, EY; Kim, JE; Mantravadi, AV | 1 |
Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Spital, G; Zeimer, M | 1 |
Cohen, SY; Nghiem-Buffet, S | 1 |
Gelisken, F; Ziemssen, F | 1 |
Agostini, H; Bertram, B; Feltgen, N; Hansen, L; Hoerauf, H; Jaissle, GB; Pielen, A; Stahl, A | 1 |
Cennamo, G; Cesarano, I; D'Amico, G; De Crecchio, G; Finelli, M; Forte, R | 1 |
Brown, DM; Chen, E; Cox, J; Lin, MY | 1 |
Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
Fraser-Bell, S; Gillies, M; Salem, W | 1 |
Chen, TC; Englander, M; Kim, IK; Miller, JW; Paschalis, EI | 1 |
García-Campos, JM; López-Gálvez, MI | 1 |
Reviews
6 review(s) available for triamcinolone acetonide and almagate
Article | Year |
---|---|
[Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antioxidants; Aptamers, Nucleotide; Bevacizumab; Humans; Lipofuscin; Macular Degeneration; Neovascularization, Pathologic; Photochemotherapy; Pregnadienediols; Ranibizumab; Retinal Drusen; Triamcinolone Acetonide | 2007 |
[Retinal vein occlusion: anti-VEGF treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Clinical Trials as Topic; Humans; Macular Edema; Prospective Studies; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2009 |
[Diabetic maculopathy. Diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Diabetic Retinopathy; Fluorescein Angiography; Glycated Hemoglobin; Humans; Intravitreal Injections; Ischemia; Laser Coagulation; Macular Edema; Ophthalmoscopy; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A | 2010 |
[Intravitreal drug therapy for retinal vein occlusion--pathophysiological mechanisms and routinely used drugs].
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood Flow Velocity; Cell Division; Combined Modality Therapy; Dexamethasone; Endothelium, Vascular; Erythropoietin; Hemodilution; Humans; Intravitreal Injections; Laser Coagulation; Long-Term Care; Papilledema; Prognosis; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Artery; Retinal Vein; Retinal Vein Occlusion; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A | 2010 |
Clinical development of new treatments for diabetic macular oedema.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract Extraction; Dexamethasone; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Pregnadienetriols; Tomography, Optical Coherence; Triamcinolone Acetonide | 2012 |
[From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Protocols; Diabetic Retinopathy; Drug Approval; European Union; Fluorescein Angiography; Humans; Laser Coagulation; Macular Edema; Microscopy, Acoustic; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, Optical Coherence; Translational Research, Biomedical; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A | 2012 |
Other Studies
12 other study(ies) available for triamcinolone acetonide and almagate
Article | Year |
---|---|
[Medical and legal issues related to the drugs currently used in the treatment of Age-Related Macular Degeneration (ARMD)].
Topics: Aptamers, Nucleotide; Drug Utilization; Humans; Macular Degeneration; Photosensitizing Agents; Porphyrins; Spain; Triamcinolone Acetonide; Verteporfin | 2006 |
Evolving European guidance on the medical management of neovascular age related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Evidence-Based Medicine; Humans; Macular Degeneration; Photochemotherapy; Pregnadienediols; Ranibizumab; Treatment Outcome; Triamcinolone Acetonide | 2006 |
Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.
Topics: Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Drug Therapy, Combination; Fluorescein Angiography; Glucocorticoids; Humans; Injections; Photochemotherapy; Photosensitizing Agents; Porphyrins; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity; Vitreous Body | 2006 |
[Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Macular Degeneration; Ophthalmology; Photochemotherapy; Porphyrins; Pregnadienediols; Ranibizumab; Societies, Medical; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Verteporfin | 2007 |
Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Glucocorticoids; Injections; Laser Coagulation; Male; Rats; Rats, Inbred BN; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drug Monitoring; Female; Humans; Injections; Intraocular Pressure; Male; Middle Aged; Ranibizumab; Retinal Diseases; Retrospective Studies; Time Factors; Tonometry, Ocular; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Humans; Immunologic Factors; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Pigment Epithelium of Eye; Ranibizumab; Retinal Detachment; Retrospective Studies; Tomography, Optical Coherence; Triamcinolone Acetonide; Visual Acuity | 2009 |
Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Prognosis; Retreatment; Retrospective Studies; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Glucocorticoids; Humans; Incidence; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Diseases; Retrospective Studies; Risk Factors; Streptococcal Infections; Triamcinolone Acetonide; Viridans Streptococci; Visual Acuity; Vitreous Body | 2011 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Topics: Academic Medical Centers; Acute Disease; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Incidence; Intravitreal Injections; Male; Massachusetts; Postoperative Complications; Ranibizumab; Retinal Diseases; Retrospective Studies; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2013 |